Aclarion updates investor deck: $14.6M cash, UK payer approvals, CLARITY trial on track for interim Q2 2026

Aclarion, Inc.

Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.
Secured UK payer approvals: three of top four private medical insurers now cover Nociscan, representing 5.2M people.
Pivotal CLARITY trial fully funded ($4.6M total); first patient estimated Q2 2025; interim results expected Q2 2026.
Expanded U.S. physician referral and commercial support; CPT Category III codes 0609T/0611T in place; Nociscan list price $1,450 vs discogram $2,000-$5,000.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.